Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 4/20 | 0.57 |
| ▸ | MET | P08581 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370132 | 0.89 | CBFB (0.46) | CBFBMETALDH1A1F2GLA | |
| SCHEMBL3846380 | 0.85 | ALDH1A1 (0.54) | CBFBMETALDH1A1F2GLA | |
| SCHEMBL359222 | 0.83 | MET (0.47) | CBFBMETALDH1A1F2GLA | |
| SCHEMBL187431 | 0.79 | FBP1 (0.44) | CBFBMETALDH1A1F2GLA | |
| SCHEMBL358693 | 0.79 | CNR1 (0.47) | CBFBMETALDH1A1F2GLA | |
| SCHEMBL358992 | 0.79 | EGFR (0.42) | CBFBMETALDH1A1F2GLA | |
| SCHEMBL359885 | 0.79 | MET (0.42) | CBFBMETALDH1A1F2GLA | |
| SCHEMBL13619702 | 0.79 | MET (0.42) | CBFBMETALDH1A1F2GLA | |
| SCHEMBL2698219 | 0.79 | ALDH1A1 (0.43) | CBFBMETALDH1A1F2GLA | |
| SCHEMBL28065817 | 0.78 | MET (0.45) | CBFBMETALDH1A1F2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310389-B1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2310389-B1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2310389-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009143477-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143477-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | HGF, HGFAC, MET | CBFB 1219/4885MET 3/4885ALDH1A1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.